It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Introduction
The hyperinflammation phase of severe SARS-CoV-2 is characterised by complete blood count alterations. In this context, the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) can be used as prognostic factors. We studied NLR and PLR trends at different timepoints and computed optimal cutoffs to predict four outcomes: use of continuous positive airways pressure (CPAP), intensive care unit (ICU) admission, invasive ventilation and death.
Methods
We retrospectively included all adult patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia admitted from 23 January 2020 to 18 May 2021. Analyses included non-parametric tests to study the ability of NLR and PLR to distinguish the patients’ outcomes at each timepoint. Receiver operating characteristic (ROC) curves were built for NLR and PLR at each timepoint (minus discharge) to identify cutoffs to distinguish severe and non-severe disease. Their statistical significance was assessed with the chi-square test. Collection of data under the SMACORE database was approved with protocol number 20200046877.
Results
We included 2169 patients. NLR and PLR were higher in severe coronavirus disease 2019 (COVID-19). Both ratios were able to distinguish the outcomes at each timepoint. For NLR, the areas under the receiver operating characteristic curve (AUROC) ranged between 0.59 and 0.81, and for PLR between 0.53 and 0.67. From each ROC curve we computed an optimal cutoff value.
Conclusion
NLR and PLR cutoffs are able to distinguish severity grades and mortality at different timepoints during the course of disease, and, as such, they allow a tailored approach. Future prospects include validating our cutoffs in a prospective cohort and comparing their performance against other COVID-19 scores.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 U.O.C. Malattie Infettive I Fondazione IRCCS Policlinico San Matteo, Pavia, Italy (GRID:grid.419425.f) (ISNI:0000 0004 1760 3027)
2 University of Pavia, Department of Electrical, Computer and Biomedical Engineering, Pavia, Italy (GRID:grid.8982.b) (ISNI:0000 0004 1762 5736)
3 U.O.C. Malattie Infettive I Fondazione IRCCS Policlinico San Matteo, Pavia, Italy (GRID:grid.419425.f) (ISNI:0000 0004 1760 3027); Diagnostiche e Pediatriche-Università di Pavia, Dipartimento di Scienze Clinico-Chirurgiche, Pavia, Italy (GRID:grid.8982.b) (ISNI:0000 0004 1762 5736)
4 U.O.C. Medicina Interna Fondazione IRCCS Policlinico San Matteo, Pavia, Italy (GRID:grid.419425.f) (ISNI:0000 0004 1760 3027)
5 U.O.C. Oncologia Medica Fondazione IRCCS Policlinico San Matteo, Pavia, Italy (GRID:grid.419425.f) (ISNI:0000 0004 1760 3027)
6 IRCCS Policlinico San Matteo, Dipartimento di Chirurgia Fondazione, Pavia, Italy (GRID:grid.419425.f) (ISNI:0000 0004 1760 3027)
7 U.O.C. Anestesia e Rianimazione Fondazione IRCCS Policlinico San Matteo, Pavia, Italy (GRID:grid.419425.f) (ISNI:0000 0004 1760 3027)